United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average rating of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $312.22.

UTHR has been the subject of a number of analyst reports. Wells Fargo & Company increased their price target on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. JPMorgan Chase & Co. increased their price target on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 12th. Oppenheimer upped their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Wedbush restated an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $287.22, for a total value of $1,033,992.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $37,338.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $287.22, for a total value of $1,033,992.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $37,338.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the transaction, the director now owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 165,728 shares of company stock worth $41,047,047. 12.50% of the stock is owned by company insiders.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Jump Financial LLC purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at about $251,000. J.P. Morgan Private Wealth Advisors LLC raised its holdings in shares of United Therapeutics by 6.1% in the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 73 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of United Therapeutics by 17.0% in the 3rd quarter. Janney Montgomery Scott LLC now owns 8,809 shares of the biotechnology company’s stock valued at $1,990,000 after acquiring an additional 1,279 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of United Therapeutics by 0.9% in the 3rd quarter. Van ECK Associates Corp now owns 9,685 shares of the biotechnology company’s stock valued at $2,188,000 after acquiring an additional 84 shares in the last quarter. Finally, Pathstone Family Office LLC purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at about $369,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $297.06 on Thursday. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $297.70. The stock’s 50 day moving average is $259.42 and its 200-day moving average is $239.10. The firm has a market capitalization of $13.18 billion, a price-to-earnings ratio of 14.05, a PEG ratio of 4.29 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.86 EPS. Sell-side analysts forecast that United Therapeutics will post 24.61 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.